Microsoft has underperformed the tech rally due to disruption fears, but BI believes it remains a leading LLM cloud provider. A new Office suite launch in the second half will drive revenue, setting the stock up for a positive surprise.
Novo Nordisk's weight‑loss drug Wegovy is seeing stronger prescription trends than consensus expects, and Bloomberg Intelligence sees potential for an upside earnings surprise.
Cheap valuations and strong earnings support Europe.
European equities are trading at a significant valuation discount (15x earnings) compared to the US (20x earnings) while delivering robust, broad-based earnings beats, presenting an opportunity to broaden exposure away from US overweights.